Should I Buy MDLN? MDLN 2026 Analysis

Should You Buy Medline Inc (MDLN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

47.300

1 Day change

2.38%

52 Week Range

47.990

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: price is in a bullish technical structure (SMA_5 > SMA_20 > SMA_200) with positive momentum, and options positioning is risk-on (low put/call).
Near-term target area: first upside test is R1 ~46.46, then R2 ~47.49 if momentum persists.
Key level to watch: staying above the pivot ~44.78 keeps the near-term bullish setup intact.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) implies an established uptrend.
Momentum: MACD histogram +0.601 and still above zero, but positively contracting → upside momentum remains, though it’s cooling (more grind-up than breakout).
RSI: RSI_6 58.71 (neutral-to-slightly-bullish), not overbought → room to continue higher without immediate mean-reversion pressure.
Levels:
- Pivot: 44.775 (important trend-defining support)
- Support: S1 43.094, S2 42.055
- Resistance: R1 46.455, R2 47.494
Tape context: stock is green (+0.68%) while S&P is down (-0.86%) → relative strength today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning (OI): Put/Call OI 0.31 (calls dominate) → bullish/positive skew in longer positioning.
Flow (volume): Put/Call volume 0.61 → still more calls than puts; mildly bullish day-to-day sentiment.
Volatility: IV30 45.45 vs HV 42.84 (small premium), while IV percentile 6.67 / IV rank 3.48 → options priced relatively cheap vs recent history (market not bracing for big moves).
Activity: Today’s option volume 1845 (~~91% of 30D avg) and OI 20354 (~~70% of 30D avg) → normal-to-moderate activity; no extreme one-day fear/mania signal.

Technical Summary

Sell

Buy

Positive Catalysts

- IPO tailwind / visibility: multiple headlines highlight strong IPO demand and scale, supporting sentiment and institutional attention.
- Balance sheet narrative: IPO proceeds aimed at paying down ~$16.5B in debt, a potential multi-quarter sentiment and credit improvement catalyst.
- Growth narrative: company projecting sales reaching ~$30B by 2026 (headline catalyst, supports bullish positioning).
- Upcoming event: Earnings scheduled 2026-02-25 (Pre-Market) — can act as a catalyst window if expectations are beaten.

Neutral/Negative Catalysts

- Leverage overhang: headline debt figure (~$16.5B) implies execution risk if deleveraging doesn’t progress as advertised.
- Profitability pressure: gross margin trend is weakening (see financials), which can cap multiple expansion.
- Post-IPO dynamics: elevated sensitivity to lockup/secondary headlines and early post-IPO positioning shifts.
- Market backdrop: broad market risk-off today (S&P -0.86%) could limit upside follow-through.

Financial Performance

Latest quarter provided: 2025/Q3
Revenue: $7.115B, +11.38% YoY → solid top-line growth.
Net income: $322M, -0.62% YoY → earnings not keeping pace with revenue.
EPS: $0.25, ~flat YoY → indicates limited operating leverage in the period.
Gross margin: 23.87%, down -3.75% YoY → key watch item; margin compression is the main fundamental drawback despite sales growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating changes or price target updates were provided in the dataset.
Wall Street-style pro view (based on available info): strong scale in medical supplies + post-IPO debt paydown story + consistent revenue growth.
Wall Street-style con view (based on available info): margin compression and leverage overhang may keep expectations constrained until profitability improves.
Influential/political trading: No recent congress trading data available; hedge funds and insiders shown as neutral (no notable recent trend).

14 Analyst Rating

Wall Street analysts forecast MDLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDLN is 47.92 USD with a low forecast of 42 USD and a high forecast of 52 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

1 Hold

0 Sell

Strong Buy

Current: 46.200

Low

Averages

47.92

High

Current: 46.200

Low

Averages

47.92

High

Tigress Financial

NULL -> Buy

initiated

$55

AI Analysis

2026-02-05

New

Reason